Generic Erleada (Apalutamide)

Apalutamide is the active ingredient in Erleada®, Janssen's androgen receptor inhibitor for advanced prostate cancer. Generic apalutamide contains the same active ingredient at the same 60 mg strength and is produced by licensed pharmaceutical manufacturers. For patients paying out of pocket, the generic can lower apalutamide cost considerably versus the originator brand. Used as prescribed by a licensed medical professional.

Apalutamide is an oral androgen receptor inhibitor used to treat advanced prostate cancer that continues to progress despite low testosterone. It is prescribed for non-metastatic castration-resistant prostate cancer (nmCRPC) and for metastatic castration-sensitive prostate cancer (mCSPC), always alongside androgen deprivation therapy (ADT). Marketed as Erleada® by Janssen, it is supplied as 60 mg tablets and is taken under the supervision of an oncologist or urologist.

Prostate cancer cells often rely on androgens such as testosterone to grow. Apalutamide binds directly to the androgen receptor and blocks testosterone and other androgens from attaching to it. By also preventing the receptor from moving into the cell nucleus and binding to DNA, apalutamide interrupts the androgen signalling that drives tumour progression. It is used together with androgen deprivation therapy, which lowers the body's testosterone, so the two approaches work on the same pathway from different angles.

Apalutamide is prescribed for adult men with advanced prostate cancer — specifically non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic castration-sensitive prostate cancer (mCSPC) — who are also receiving androgen deprivation therapy. It is not suitable for everyone: suitability depends on cancer type, staging, cardiovascular and bone health, and other medicines being taken. Only a licensed oncologist or urologist can decide whether apalutamide is appropriate, and treatment is monitored throughout.

The usual dose of apalutamide is 240 mg once daily, taken as four 60 mg tablets together, with or without food, alongside ongoing androgen deprivation therapy. Tablets should be swallowed whole. If a dose is missed or side effects occur, your oncologist may pause treatment or reduce the dose to 180 mg or 120 mg. Dosing is individual and must be set and adjusted only by your prescribing doctor — this information is for general guidance and is not a substitute for medical advice.

Never change your dose on your own.

Common side effects of apalutamide include fatigue, skin rash, high blood pressure (hypertension), falls and fractures, and joint pain (arthralgia). Some men also experience diarrhoea, weight loss, hot flushes or reduced appetite. Rarely, serious reactions such as severe skin rash, seizures or heart problems can occur. Any severe rash, fall, chest symptoms or unusual bruising should be reported to your care team straight away. Your doctor will monitor for these effects during treatment.

Report new or worsening symptoms to your doctor promptly. This is not a complete list — see the patient information leaflet.

Store as directed on the patient information leaflet, usually at room temperature away from moisture and out of reach of children. Always follow the storage guidance supplied with your medicine.

Apalutamide belongs to the same class of second-generation androgen receptor inhibitors as enzalutamide (branded Xtandi) and darolutamide. All three block the androgen receptor and are given alongside androgen deprivation therapy, but they differ in their approved settings, dosing schedules and side-effect profiles. Choosing between them is a clinical decision based on the type and stage of prostate cancer, other health conditions and tolerability. This page does not compare how well the drugs work — only your oncologist can weigh those factors for your situation.

Erleada® carries a high list price because Janssen prices the originator brand to recover the cost of research, clinical trials and marketing, and it remains under patent protection in several markets. That is why searches for the generic for Erleada are so common among patients paying out of pocket. Generic apalutamide contains the identical active ingredient at the same 60 mg strength, but is made by licensed manufacturers who did not fund the original development, so the apalutamide cost is substantially lower. The saving is on price alone — not on the medicine itself.

Apalutamide is a long-term daily treatment, and your care team will monitor you throughout. Blood pressure is checked regularly because hypertension is common, and because falls and fractures can occur, bone health and fall risk are assessed — some men are offered bone-protective measures. Skin rash is a frequent side effect that should be reported early, as it occasionally becomes severe. Fatigue and joint pain are also common. Always take apalutamide exactly as prescribed by a licensed medical professional and report new or worsening symptoms promptly.